Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
First-in-Human Single Ascending Dose of SHR0302
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT02423538
- Locations
- 🇨🇳
First Affiliated Hospital of Fourth Military Medical University, Xi'an, Shanxi, China
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT02422199
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02409394
- Locations
- 🇨🇳
West Hospital, Sichuan University, Chengdu, Sichuan, China
A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT02406872
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Peking, Beijing, China
Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 304
- Registration Number
- NCT02407210
- Locations
- 🇨🇳
Beijing ANZHEN Hospital, Beijing, China
A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02403440
- Locations
- 🇨🇳
West Hospital, Sichuan University, Chengdu, China
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
- Conditions
- Colorectal Cancer RecurrentColorectal Cancer Metastatic
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 543
- Registration Number
- NCT02390947
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Third Xiangya Hospital of Cental South University, Changsha, Hunan, China
🇨🇳Cancer Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer
- Conditions
- HER2 Positive Gastric Cancer
- Interventions
- Drug: Pyrotinib/Pyrotinib with Docetaxel
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT02378389
- Locations
- 🇨🇳
Beijing Cancer Hospital, Peking University, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT02366351
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT02366377